East China Pharmaceutical: The subsidiary Yidala Feng Tablet's application for listing approval has been accepted.

On the evening of July 30th, Huadong Pharmaceutical announced that its wholly-owned subsidiary Zhongmei Huadong received a "Notice of Acceptance" issued by the National Medical Products Administration for the marketing authorization application of Edaravone tablets for the treatment of acute ischemic stroke. Edaravone is a heavyweight variety in the field of nervous system drugs. Compared to the Edaravone injection given in hospitals for 14 days, Edaravone oral tablets can reduce the use of medical resources and are suitable for patients to self-administer long-term medication.